LeMaitre Vascular Reports Strong Q2 2026 Growth on Artegraft Momentum — LeMaitre Vascular, Inc.

Event summary

Q2 2026 sales reached $70.4 million, up 10% year-over-year with organic growth of 10%.
Gross margin expanded by 210 basis points to 72.1%, driven by higher prices and operational efficiencies.
Artegraft sales surged 34%, becoming the company's fastest-growing product while accounting for 21% of total sales.
Cash position increased sequentially by $9 million to $376.2 million, providing strategic flexibility.
Guidance for full-year 2026 sales was raised to a midpoint of $276.3 million, representing 11% growth.

The big picture

LeMaitre Vascular's Q2 2026 results highlight the strategic success of its Artegraft international launch, which is now approved in 56 countries. The company's focus on higher-margin products and operational efficiencies aligns with broader industry trends toward specialty vascular solutions. With a strong cash position and raised guidance, LeMaitre appears well-positioned to capitalize on growing demand for peripheral vascular treatments.

What we're watching

Product Diversification: How LeMaitre will balance Artegraft's rapid growth with other product lines, particularly catheters which faced a 11% decline due to recall-driven overstocking.
International Expansion: The pace at which the company can successfully execute its six international warehouse expansions and direct sales model transitions in new countries.
Operational Efficiency: Whether LeMaitre can sustain its improved gross margins through continued headcount restraint and operational improvements.